Clinical Trials

24 enrolled

CNS

Neurofibromatosis 1

NCT02143466 2026-01-30

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

344 enrolled

Advanced Non Small Cell Lung Cancer

NCT04590235 2026-01-30

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

32 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02546661 2025-12-29

BISCAY

MyeloidOther hematologic neoplasm

117 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT03326310 2025-12-29

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

Phase 1 Recruiting

18 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT00463814 2025-11-13

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

58 enrolled

Neoplasms

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

BreastDermatologicGastrointestinalGenitourinaryThoracic

140 enrolled

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT03162627 2025-10-14

Selumetinib and Olaparib in Solid Tumors

90 enrolled

Breast

Breast Neoplasms

NCT03833427 2024-11-07

MK-5618-001

32 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02768766 2023-08-31

Intermittent Selumetinib for Uveal Melanoma

42 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT01783197 2023-08-04

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

39 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03745989 2023-07-27

MK-8353-014

30 enrolled 19 charts

Neoplasm Metastasis

NCT01160926 2023-04-24

DREAMtherapy

31 enrolled

Rectal Neoplasms

NCT02503358 2023-03-21

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

23 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01146756 2023-02-15

MEKRT

21 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01134601 2021-12-01

A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

1 enrolled 7 charts

Rectal Neoplasms

NCT01586624 2021-10-07

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

61 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00085787 2020-10-14

A Study of ARRY-142886 in Patients With Advanced Cancer

57 enrolled

Advanced Cancer

NCT01287130 2019-12-17

AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer

10 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

BreastDermatologicGastrointestinalThoracic

58 enrolled

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT01021748 2018-08-07

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

63 enrolled 17 charts

Locally Advanced or Metastatic Solid Tumors

NCT01605916 2016-10-21

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

33 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02322749 2016-08-31

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

48 enrolled 16 charts

Neoplasms

NCT02063230 2016-07-21

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

32 enrolled 12 charts

Solid Tumors

NCT01242605 2016-05-13

ABC-04

13 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT01949870 2016-05-13

Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

6 enrolled 6 charts

Biliary Tract Neoplasms

NCT02238782 2016-04-05

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

21 enrolled 4 charts

Neoplasms

NCT01061749 2016-01-25

Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

30 enrolled

Adult Solid Neoplasm

NCT02056392 2015-11-09

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

54 enrolled 31 charts

Solid Tumours

NCT01931761 2015-06-30

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers

6 enrolled

Solid Tumours

NCT02063204 2015-06-30

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

24 enrolled

Renal Insufficiency

NCT02093728 2015-06-30

To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

26 enrolled

Solid Tumours

NCT00710515 2014-08-13

Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies

30 enrolled

Dermatologic

Melanoma

NCT01974349 2014-08-13

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

39 enrolled

Solid Tumours

NCT01960374 2014-06-02

Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK

117 enrolled

Healthy Volunteers Pharmacokinetic Study

NCT01217450 2014-05-29

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

33 enrolled